December 30, 2024 1 min read The top glaucoma articles on Healio in 2024 included an overview of a more holistic approach to managing the disease as well as safety and efficacy data for a sustained-release bimatoprost drug delivery platform. Check out these stories and more below. Check out the top glaucoma articles on Healio in 2024. Image: Adobe Stock … [Read more...] about Glaucoma: Top items in ophthalmology for 2024
News
Wrapping up another year in eye care: 2024 in review from Ophthalmology Times Europe
Another year is coming to its end. We spent 2024 celebrating the 20th anniversary of Ophthalmology Times Europe. That milestone wouldn’t be possible without readers like you, who refer back to our print magazine, digital edition, eNewsletters and video interviews day after day. Throughout the year, our industry has experienced major victories. We’ve navigated challenges and … [Read more...] about Wrapping up another year in eye care: 2024 in review from Ophthalmology Times Europe
VIDEO: OCS-01 eye drop shows efficacy, safety for treatment of DME
December 30, 2024 3 min watch CHICAGO — In this Healio Video Perspective from the AAO meeting, Arshad M. Khanani, MD, MA, FASRS, shares promising data from an ongoing phase 2/3 study investigating OCS-01, an eye drop for the treatment of diabetic macular edema. “In stage one, we saw efficacy signals in every single parameter we looked at, … [Read more...] about VIDEO: OCS-01 eye drop shows efficacy, safety for treatment of DME
Playing matchmaker with Schlemm canal surgery
Reviewed by Sheng Lim, MD, FRCOphth; and Karl Mercieca, MD, FRCOphth, FEBOS-GLDuring the European Society of Cataract and Refractive Surgeons meeting, Sheng Lim, MD, FRCOphth, professor of glaucoma studies at St Thomas’ Hospital and King’s College London, both in England, and Karl Mercieca, MD, FRCOphth, FEBOS-GL, director of glaucoma services and lead surgeon at the University … [Read more...] about Playing matchmaker with Schlemm canal surgery
How intravitreal anti-vascular endothelial growth factor initial dosing impacts patient outcomes in diabetic macular oedema
Intravitreal anti-vascular endothelial growth factor (VEGF) treatment for diabetic macular oedema (DME) may begin with several initial monthly doses. Characteristics, treatment patterns and outcomes were compa... … [Read more...] about How intravitreal anti-vascular endothelial growth factor initial dosing impacts patient outcomes in diabetic macular oedema
Delayed spontaneous resolution of a double anterior chamber following deep anterior lamellar keratoplasty (DALK)
This study reports a rare case of delayed spontaneous resolution of double anterior chambers (AC) resulting from non-rhegmatogenous Descemet membrane detachment (DMD) after deep anterior lamellar keratoplasty ... … [Read more...] about Delayed spontaneous resolution of a double anterior chamber following deep anterior lamellar keratoplasty (DALK)
VIDEO: ImprimisRx highlights new offerings for ocular surgery
December 29, 2024 1 min watch CHICAGO — In this Healio Video Perspective from the AAO meeting, John Saharek, CEO and president of ImprimisRx, previews two recently launched ophthalmic surgery products. According to Saharek, Repackaged Vigamox (moxifloxacin 5 mg/mL) is an injectable to be used during surgery and Povicaine (povidone-iodine … [Read more...] about VIDEO: ImprimisRx highlights new offerings for ocular surgery
Part 7: Ask the Experts: What problem in ophthalmology do you wish there was a solution for?
This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.Video Transcript:Editor's note: The below transcript has been lightly edited for clarity.Vikas Chopra, MD:Yeah. I mean, if we can cure blindness, that would be amazing. So, you know, we are, of course, moving in that direction with, you know, … [Read more...] about Part 7: Ask the Experts: What problem in ophthalmology do you wish there was a solution for?
Brolucizumab shows promise over aflibercept for diabetic macular edema in meta-analysis
A recent study that compared 2 anti-vascular endothelial growth factor drugs for treating diabetic macular edema (DME) found that brolucizumab (Beovu, Novartis) was non-inferior in functional outcomes and superior to aflibercept (Eylea, Regeneron Pharmaceuticals) in anatomic parameters,1 according to first author Leonardo B. Justino from the Division of Medicine, Federal … [Read more...] about Brolucizumab shows promise over aflibercept for diabetic macular edema in meta-analysis
FDA news: Top items in ophthalmology for 2024
December 27, 2024 1 min read Healio’s top FDA articles in ophthalmology this year included updates on the Vabsymo prefilled syringe, two new aflibercept biosimilars and an oral therapy for Stargardt disease. Check out 2024’s top FDA news below. Check out 2024’s top FDA news. … [Read more...] about FDA news: Top items in ophthalmology for 2024